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PRH (proline-rich homeodomain protein) is strongly
expressed in the hematopoietic compartment. Here we
show that PRH is a repressor of transcription in hema-
topoietic cells. A fragment of PRH that includes the
homeodomain can bind to TATA box sequences in vitro
and can also bind to the TATA box-binding protein. PRH
represses transcription from TATA box-containing pro-
moters in intact cells but does not repress transcription
from a promoter lacking a TATA box. A mutation in the
PRH homeodomain that blocks binding to DNA but that
has little or no effect on binding to the TATA box-bind-
ing protein significantly reduces the ability of the pro-
tein to repress transcription and provides the first clear
demonstration that a homeodomain can bring about
transcriptional repression in vivo by binding to a TATA
box. However, we also show that mutation of the PRH
homeodomain does not block the ability of PRH to re-
press transcription when this protein is tethered up-
stream of the TATA box via a heterologous DNA-binding
domain. PRH also contains an N-terminal proline-rich
repression domain that is separate from the homeodo-
main. Deletion mapping suggests that this repression
domain contains at least two regions that both inde-
pendently contribute to transcriptional repression.
Homeodomain proteins are a family of transcription factors
that are important regulators of gene expression in all eu-
karyotes (1). The homeodomain is a 60-amino acid motif that
mediates sequence-specific binding to DNA (2). The homeodo-
main can also make protein-protein contacts that modulate the
ability of the homeodomain proteins to enter the nucleus (3),
bind DNA (4), and regulate transcription (5, 6). PRH (proline-
rich homeodomain protein) was first identified in differentiated
avian hematopoietic and liver cells (7) and was subsequently
found to be conserved in human, Xenopus, mouse, and rat
where it has also been called XHex or Hex (8–10). PRH is
expressed in the anterior endoderm in developing Xenopus and
mouse embryos (11, 12) and is present in fetal liver, thyroid,
and lung (13). It is a member of the tinman family of homeodo-
main-containing proteins that includes several transcription
factors essential for the development of cardiac tissue (14).
Within the hematopoietic compartment PRH mRNA is ex-
pressed in B-cells, myelomonocytic cells, and erythroid cells but
not in T-cell lineages (7, 15), and in general, PRH mRNA levels
are down-regulated as hematopoietic cells differentiate (15,
16). Several studies suggest a role for PRH in the regulation of
cell proliferation and differentiation. PRH is transiently ex-
pressed in vascular endothelial cells in Xenopus embryos and
overexpression of Xenopus PRH disrupts developing vascular
structures and brings about an increase in the number of these
cells (8). In addition, overexpression of PRH in Myb-Ets trans-
formed multipotential hematopoietic cells inhibits cell growth,
whereas the expression of truncated PRH derivatives alters the
ability of these cells to differentiate (16). Finally, PRH interacts
with PML (promyelocytic leukemia protein), a growth control
protein, in several leukemic cell lines (17) and is up-regulated
in some B-cell leukemias (18).
PRH has recently been reported to repress transcription in
liver cells (10). However, the mechanism or mechanisms
whereby this protein brings about transcriptional repression
have yet to be determined. Transcriptional repression mecha-
nisms can be broadly classified into four main categories: steric
hinderance, quenching, direct repression, and the modulation
of chromatin structure. Many repressor proteins hinder steri-
cally the binding of transcription activators or general tran-
scription factors, and this is often referred to as passive repres-
sion. For example, the Drosophila homeodomain protein
Engrailed (En) blocks the action of the activator protein Fushi
tarazu by competing for a common binding site on DNA (19). In
vitro studies have demonstrated that En can also repress tran-
scription by directly competing with the TATA box-binding
protein (TBP)1 for binding to a TATA box (20). Similarly, in
vitro studies with Even-skipped (Eve), another Drosophila ho-
meodomain protein, have suggested that Eve can repress tran-
scription by a mechanism that involves the cooperative binding
of Eve protein to low affinity Eve binding sites that lie adjacent
to TATA box sequences or activator protein binding sites. This
results in Eve sterically blocking DNA binding by TBP or the
activator protein Zeste (21, 22). In quenching repressor pro-
teins mask the activity of locally bound activator proteins. For
example, the Drosophila protein Kruppel can bind to Sp1 and
prevent this protein activating transcription (23). In addition,
repressor proteins can interfere with the targets of the activa-
tors, such as components of the core transcription machinery, a
process known as direct repression. Kruppel has been shown to
bind in vitro to the small subunit of TFIIE (24), and a number
of repressor proteins have been shown to bind to TBP includ-
ing: Eve (25), the mouse homeodomain protein Msx-1 (26), the
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unliganded thyroid hormone receptor (27), and the global re-
pressor proteins Dr1 (28) and Mot1 (29).
Several repressor proteins interact with chromatin stabiliz-
ing factors or chromatin assembly complexes. The best under-
stood chromatin stabilizing proteins are probably the histone
deacetylases. Histone deacetylation is thought to tighten the
nucleosome-DNA interaction with the consequence that the
access of transcription factors to their binding sites is hindered.
The mammalian protein YY1 interacts directly with a number
of proteins involved in transcription, including mRPD3, a his-
tone deacetylase (30). Many other transcriptional repressors
interact with deacetylases indirectly via corepressor proteins.
For example, the Max-Mad repressor complex and the unligan-
ded thyroid hormone receptor protein interact with mSin3a/
mSin3b and the closely related corepressors N-CoR and SMRT,
respectively. These corepressors then effect the repression of
transcription through the recruitment of histone deacetylases
(31, 32).
Several repressor proteins have been shown to use more than
one mechanism to bring about transcriptional repression. For
example, the En homeodomain protein appears to utilize at
least four different mechanisms: En can compete with activa-
tors (19), compete with TBP for binding to DNA in vitro (20),
interact directly with the Drosophila corepressor protein Grou-
cho (33, 34), and, in addition, En contains a repression domain
that is separate from the Groucho interacting region and that
works by an as yet unknown mechanism (35). In this study we
examine the ability of PRH to regulate transcription in hema-
topoietic cells, we investigate the PRH repression domains, and
we explore the mechanisms whereby PRH might bring about
transcriptional repression.
MATERIALS AND METHODS
Plasmid DNAs Used in This Study
Reporters—The pTK luciferase reporter construct has been described
previously (36). The pTK-GAL luciferase construct was made by cloning
five GAL4 binding sites between the EcoRI and BamHI sites of pTK.
The pTK-PRH luciferase construct was made by cloning five PRH
binding sites identified in site selection experiments (7) between the
HindIII and SmaI sites of pTK. The HS1-luciferase reporter is de-
scribed in (37) and was supplied by Dr. K. Gaston (University of Bristol,
Bristol, UK). The SV40 promoter-luciferase reporter is the pGL-3 pro-
moter vector from Promega. The transfection control plasmids are pSV-
b-galactosidase control vector (pSV-lacZ) from Promega and the pRSV-
b-galactosidase (pRSV-lacZ), which contains the Rous sarcoma virus
long terminal repeat placed upstream of the lacZ gene.
Expressors—pCMV-PRH was made by cloning the 1.5-kilobase PRH
cDNA fragment described in Ref. 7 into the EcoRI site of pCMV (Pro-
mega). pSG424 has been described previously (38). The N-terminal
glutamine-rich Sp1 activation domain (base pairs 1–510) and full-
length HIV-1 TAT (base pair 831–1091 of the HIV genome) were cloned
in frame with GAL4 DBD into the multiple cloning site of pSG424.
These plasmids were kindly supplied by Dr. M. Dickens (University of
Leicester, Leicester, UK). pMLV-GAL147plink has been described pre-
viously (39). GAL4-VP16 was made by cloning a polymerase chain
reaction fragment encoding the viral VP16 acidic activation domain
(base pairs 1680–1923) in frame between the SalI and SpeI sites of
pMLV-GAL147plink. The plasmid pcDNA3-TLE1 expresses human
TLE1 (40) and was kindly supplied by Dr S. Stifani (McGill University,
Montreal, Canada). To construct the pBlueScript-TBP plasmid used for
in vitro transcription and translation experiments, an EcoRI-HindIII
fragment encoding the TBP cDNA was isolated from the plasmid
pGEXKG-TBP (41) kindly supplied by Dr D. Hornby (University of
Sheffield, Sheffield, UK). This fragment was cloned between the EcoRI
and HindIII sites of pBlueScript II (Stratagene).
GAL4-PRH Fusion Proteins—The PRH cDNA described in Ref. 7 was
cloned into the EcoRI site in pBlueScript (Stratagene) to create pBSK-
PRH16.3. This plasmid was cut with SalI (which is located 59 to the first
PRH ATG codon) and NarI (98 bp after the ATG), and an oligonucleo-
tide corresponding to the coding region from the ATG to the NarI site
was cloned between the SalI and NarI sites. A SmaI-SmaI fragment
was then removed from the 39-noncoding region, and the vector was
self-ligated to create pBSK-PRH18.3. For GAL4-PRH 1–277, a SalI-
SpeI fragment from pBSK-PRH18.3 was cloned into pMLV-
GAL147plink between the SalI and SpeI sites. GAL4-PRH 1–141 was
constructed from pBSK-PRH18.3 by cutting with NotI and cloning in a
linker with a stop codon and a SpeI site to create pBSK-PRH18.341; the
423-bp SalI-SpeI fragment was then transferred to pMLV-
GAL147plink. For GAL4-PRH 28–141, plasmid GAL4-PRH 1–141 was
cut with SalI and PstI (removing bp 1–84) blunted with T4 polymerase
and religated. For GAL4-PRH 81–141, an AccI fragment was cut from
pBSK-PRH18.341. This corresponds to amino acids (aa) 81–141 and
some pBlueScriptKII vector sequence. The AccI sites were filled in with
Klenow and cloned into the pMLV-GAL147plink SalI and SpeI sites
that had been cut and filled in by T4 polymerase. This recreates the
SalI site, but the SpeI site is lost. For GAL4-PRH 107–141, GAL4-PRH
1–141 was cut with SalI (aa 1) and filled in and then cut with ApaI (aa
105), trimmed back with T4 polymerase, and religated. Thus, the 1–107
SalI to ApaI fragment was removed, leaving the 107–141 PRH frag-
ment and the vector on religation recreated the 59SalI site. For GAL4-
PRH 1–105, an ApaI fragment from pBSK-PRH18.3 was cloned into the
SmaI site of pBSK to make pBSK-PRH18.305. The ApaI fragment
contained the 59SalI site and aa 1–105 of PRH. The 315-bp SalI-SpeI
PRH fragment from this vector was cloned into pMLV-GAL147plink.
For GAL4-PRH 28–105, pBSK-PRH18.305 was cut with PstI and SalI,
blunted with T4 polymerase, and religated to itself, thus removing aa
1–28 of PRH and the 59SalI site to create pBSK-PRH18.3205. An
XhoI-SpeI PRH fragment from this vector was cloned into pMLV-
GAL147plink. The XhoI-SpeI PRH fragment has three extra codons 59
to aa 1 in PRH, so GAL4-PRH 28–105 contains three extra codons
between the GAL4 DBD and aa 1 of PRH. For GAL4-PRH 1–125, an
ApaI (aa 105–141)-SpeI fragment was removed from GAL4-PRH 1–141
leaving aa 1–105. An oligonucleotide linker coding for amino acids
105–125 (from the ApaI site) and including a SpeI site was cloned into
this plasmid. For GAL4-PRH 107–277, the ApaI SpeI 510-bp PRH
fragment from pBSK-PRH18.3 was isolated after the ApaI site was
blunted with T4 polymerase. This fragment was cloned into the SalI
SpeI site of pMLV-GAL147plink after the SalI site in the vector was
filled in with Klenow. This creates GAL4-PRH 107–277 and recreates
the SalI site at the 59 end. For GAL4-PRH 49–141, GAL4-PRH 143–
277, GAL4-PRH 143–210, and GAL4-PRH 202–277 were made by po-
lymerase chain reaction from GAL4-PRH 1–277 using 59 oligonucleo-
tides carrying a SalI site and a 39 oligonucleotides carrying a SpeI site.
The polymerase chain reaction fragments were cloned into the SalI and
SpeI sites of pMLV-GAL147plink: 49–56, 59-GTCGACCCGGCCCCCC-
ACTCCCTGCCCGCC-39; 61–65, 59-GTCGACACGCTGCCGTCGCCC-
AAC-39; 143–148, 59-GTCGACAAGAGGAAGGGTGGCCAG-39; 202–
208, 59-GTCGACCTGAAGCAGGGAGAACCCCCAGG-39; 125–120, 59-
ACTAGTGTCCTGGCGGATCAGTGC-39; 141–136, 59-ACTAGTCAGC-
GGCCGCTGGATGA-39; 210–204, 59-ACTAGTGGTGGCCTGGGGGTT-
CTCCTG-39; and 277–270, 59-ACTAGTGCGTGTGGCGCTGTAGAA-
GCCTTT-39.
Bacterial Expression Plasmids—The histidine-tagged PRH expres-
sion vectors were created by cloning the NotI-EcoRI fragment from
pBSK-PRH16.3 containing sequences encoding the PRH homeodomain
and C terminus, together with an XhoI-NotI linker, between the XhoI
and EcoRI sites of pTrcHisA (Invitrogen) to create pTrcHisA-PRH 137–
277. A NotI-SmaI PRH fragment carrying the N194A mutation de-
scribed below was transferred from the pBSK-PRHHDM 18.3 clone into
pTrcHisA-PRH 137–277, replacing the wild type PRH sequence and
creating pTrcHisA-PRHHDM 137–277.
The GST-PRH 1–141 expression vector was created by cloning the
DNA sequence encoding the PRH N terminus (amino acids 1–141), as a
SalI-SpeI fragment from pGAL4-PRH 1–141 into pGEX20T that had
been cut with XhoI and SpeI, creating pGEX20T-PRH 1–141. pGEX20T
is a derivative of pGEX2T (Amersham Pharmacia Biotech) and contains
unique XhoI and SpeI restriction sites in the polylinker downstream of
the GST moiety. The GST-tagged human PRH N terminus was a gift
from Dr. G. Manfioletti (University of Trieste, Trieste, Italy). Briefly,
the human PRH N terminus (amino acids 1–131) was cloned as an
EcoRI fragment into pGEX3X (Amersham Pharmacia Biotech). All con-
structs were checked by DNA sequencing.
Cell Culture and Transient Transfection Assays
BM2 cells were grown in RPMI 1640 (Life Technologies, Inc.) 25 mM
HEPES medium supplemented with 10% tryptose phosphate, 10% glu-
tamine, 10% fetal calf serum, and 5% chicken serum to a density of
;1 3 106 cells/ml. The cells were collected by centrifugation and then
resuspended in RPMI 1640 25 mM HEPES plus 10% fetal calf serum to
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a density of 5 3 107 cells/ml. 1 3 107 cells plus 5 mg each of the
luciferase and lacZ reporter plasmids and the amount of expressor
plasmid indicated under “Results” were electroporated using a Bio-Rad
Genepulser (0.25 V, 960 microfarads). Cells were rested for 10 min and
then incubated overnight in 10 ml of supplemented medium. After 24 h
the cells were harvested, and luciferase activity was assayed using the
Promega luciferase assay system according to the manufacturer’s in-
structions. b-Galactosidase assays were performed as an internal con-
trol for transfection efficiency. After subtraction of background, the
luciferase counts were normalized against the b-galactosidase value.
QT6 cells were grown in Dulbecco’s modified Eagle medium (Life Tech-
nologies, Inc.) supplemented with 10% fetal calf serum and 2% chicken
serum. 3 3 106 QT6 cells were transfected with 5 mg of each of the
reporter plasmids and 1 mg of expressor plasmid by calcium phosphate
precipitation. Cell extracts were made 18 h after transfection as de-
scribed for BM2 cells. At least two independent batches of expressor and
reporter constructs were assayed in multiple experiments, and the
results were averaged.
Site-directed Mutagenesis
Mutagenesis of PRH asparagine 194 to alanine was carried out in
pBSK-PRH18.3 using a mutant oligonucleotide: 59-AAAACGTGGTTC-
CAGGCCCGCAGAGCCAAATG-39 and a QuikChange mutagenesis kit
(Stratagene) according to the manufacturer’s instructions. The under-
lined positions mismatch the template and introduce the desired se-
quence change. After sequencing the mutated clone (pBSK-PRHHDM
18.3), a NotI-SpeI PRH fragment carrying the mutation was transferred
from pBSK-PRHHDM 18.3 into pMLV-GAL147plink-PRH (GAL4-PRH),
replacing the wild type PRH sequence and creating pGAL4-PRHHDM.
Proteins Used in This Study
Histidine-tagged fusion proteins were purified from bacterial lysate
by chromatography on a nickel (Ni21-NTA-agarose) column (Qiagen)
essentially according to the manufacturer’s instructions. The eluted
proteins were assayed for purity by SDS-PAGE followed by staining
with Coomassie Blue and quantified using the Bio-Rad phosphoric acid
protein assay. GST fusion proteins were purified over glutathione-
Sepharose 4B beads (Sigma) and assayed for purity and concentration
as above.
Circular Dichroism
Circular dichroism spectra of pTrcHisA-PRH 137–277 and pTrcHisA-
PRHHDM 137–277 proteins (3.3 and 6.4 mM, respectively, in 25 mM
phosphate buffer, pH 7.9) were obtained using a JY CD6 CD spectrom-
eter with 5-mm-pathlength cells. Spectra were collected at 1-nm incre-
ments, using a 20-s integration time. The spectra have been corrected
for concentration differences.
Electrophoretic Mobility Shift Assays
Single stranded oligonucleotides (100 ng) were 59-end labeled with
[g32P]ATP using T4 polynucleotide kinase. After annealing to the com-
plementary oligonucleotide free label was removed using Sephadex G50
spin columns. Labeled oligonucleotides (20,000 cpm) were incubated
with purified proteins in the quantities indicated in the figures in
binding buffer (10% glycerol, 1 mM MgCl2, 20 mM Tris, pH 8.0, 1 mM
dithiothreitol, 50 mM NaCl, 0.04 mg/ml dI-dC, 0.1 mg/ml bovine serum
albumin). After 30 min on ice, complexes were resolved on 6% nonde-
naturing polyacrylamide gels run in 13 TBE and visualized using a
PhosphorImager.
In Vitro Binding Assays
Transcription and translation was carried out using a TNT kit (Pro-
mega) according to the manufacturer’s protocol. Approximately 50–100
mg of affinity-purified histidine-tagged fusion protein (PRH 137–277 or
PRHHDM 137–277) was bound to 100 ml of nickel-NTA beads (Qiagen)
under the conditions recommended in the manufacturer’s protocol. To
assay for specific interactions 10 ml of [35S]methionine-labeled in vitro
translated TBP was added and incubated in binding buffer (20 mM
HEPES, pH 7.8, 200 mM KCl, 5 mM MgCl2, 0.5 mM dithiothreitol, 0.5%
Nonidet P-40, 50 ng/ml bovine serum albumin) with gentle agitation for
60 min at 4 °C. The beads were washed six times with 1 ml of binding
buffer. Bound proteins were eluted with elution buffer (250 mM imid-
azole, 300 mM NaCl, 50 mM NaH2PO4) and analyzed by SDS-PAGE and
fluorography.
Western Blotting
QT6 cells were harvested after transient transfection and lysed in
luciferase assay lysis buffer (Promega). The supernatant (which con-
tains no detectable signal with antibodies against GAL4 1–147) was
removed and used for b2galactosidase and luciferase assays. The chro-
matin pellet was resuspended in 20 ml of 100 mM HEPES, pH 7.9, 5 mM
MgCl2, and 1 mM CaCl2 containing sufficient DNase I to digest the
sample in ;5 min at 20 °C. After the DNase I digestion, 20 ml of 23 SDS
loading buffer was added, and the sample was boiled for 2 min. A
proportional amount of each sample was separated by SDS-PAGE and
blotted onto an Immobilon membrane. GAL4 fusion proteins were then
detected using a mixture of two monoclonal antibodies 2GV3 and 3GV2
(a gift from Professor P. Chambon, (42) and an ECL kit (Amersham
Pharmacia Biotech).
RESULTS
PRH Is a Repressor of Transcription in Hematopoietic Cells—
The PRH protein consists of three regions (Fig. 1A). The N-
terminal region (aa 1–143) is 20% rich in proline residues and
13% rich in alanine residues and is separated by the homeodo-
main (aa 144–203) from a C-terminal region (aa 204–277) 25%
rich in acidic residues. Both proline/alanine rich regions and
acidic regions are commonly found in the regulatory domains of
transcription factors. The PRH cDNA was originally cloned
from an avian cDNA library derived from BM2 cells, an avian
myeloblastosis virus-transformed hematopoietic cell line (7). To
investigate whether PRH functions as a transcription factor in
BM2 cells, we performed transient cotransfection assays.
Previous site selection experiments using a truncated PRH
protein (consisting of the PRH homeodomain and C terminus)
determined the consensus PRH binding site to be 59-(C/T)(A/
T)ATT(A/G)-39 (7). Five copies of a PRH binding site identified
in these experiments were placed upstream of the luciferase
gene under the control of the thymidine kinase minimal pro-
moter (TK) to create the reporter plasmid pTK-PRH (Fig. 1A).
Plasmid pCMV-PRH expresses PRH under the control of the
cytomegalovirus promoter. This expression plasmid was tran-
siently cotransfected into BM2 cells along with pTK-PRH. The
effect of pCMV-PRH on luciferase activity was compared with
the effect of the empty expression vector pCMV. To normalize
for transfection efficiency, a constant amount of a control plas-
mid containing the lacZ gene under the control of the SV40
promoter and enhancer was also cotransfected. As can be seen
from the data shown in Fig. 1B, increasing amounts of the
pCMV-PRH plasmid bring about a dramatic decline in lucifer-
ase activity. As little as 10 ng of the PRH expression plasmid is
sufficient to bring about a 50% decrease in TK promoter activ-
ity, suggesting that PRH is a potent repressor of transcription.
A number of homeodomain proteins have been shown to
repress transcription even in the absence of their cognate bind-
ing sites. To determine whether repression of the pTK-PRH
promoter by PRH is dependent upon the presence of PRH
binding sites, we cotransfected pCMV-PRH with the pTK re-
porter lacking PRH binding sites. Increasing amounts of
pCMV-PRH bring about increasing repression of this reporter
(Fig. 1C). However, in this case a 10-fold higher amount of
pCMV-PRH (100 ng) is required to bring about a 50% repres-
sion of promoter activity. Thus, PRH is also capable of repress-
ing transcription in the absence of PRH binding sites.
PRH Represses Activated Transcription—In the experiments
described above PRH was able to repress transcription from a
TK promoter lacking PRH binding sites. To establish whether
PRH could repress activated transcription from this promoter,
five copies of a GAL4 binding site were inserted upstream of
the minimal TK promoter to create pTK-GAL (Fig. 2A). Plas-
mid pSG424 carries the yeast GAL4 DBD and was used to
express a number of activator-GAL4 fusion proteins (38). Tran-
scription activation domains from the Sp1 and HIV-1 TAT
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proteins were fused in frame with the GAL4 DBD present in
pSG424. The HSV-1 VP16 acidic activation domain was also
expressed as a GAL4 DBD fusion using the expression vector
pMLV-GAL147plink (Fig. 2B). Between 50 and 200 ng of each
expression plasmid or equivalent amounts of the empty vectors
were transiently cotransfected into BM2 cells along with the
pTK-GAL reporter (Fig. 2C). In each case plasmids expressing
the activator-GAL4 fusion proteins increase luciferase activity.
Activation levels range between 6- and 85-fold above basal
TK-GAL promoter activity depending on the activator (Fig.
2C). Increasing amounts of pCMV-PRH were then cotrans-
fected into BM2 cells along with each activator-GAL4 expres-
sion plasmid. In each case, PRH is able to repress activated
transcription (Fig. 2C). Because each fusion protein contains a
different class of activation domain (Sp1 is glutamine-rich,
VP16 is acidic, and TAT does not contain a predominance of a
single kind of amino acid), these data suggest that binding
site-independent repression by PRH is not activator-specific.
PRH Strongly Represses TATA Box-dependent Promot-
ers—In vitro the homeodomain protein En can bind directly to
FIG. 1. PRH is a repressor of tran-
scription. A, the top line is a schematic
representation of avian PRH. The second
and third lines are schematic representa-
tions of the reporter plasmids pTK and
pTK-PRH, respectively. The reporter
plasmids contain the minimal TK pro-
moter (from 2109 to 152) located up-
stream of the luciferase gene. pTK-PRH
contains five PRH binding sites upstream
of the TK promoter. B, the graph shows
the relative promoter activity found in
BM2 cell extracts 24 h after transient co-
transfection with increasing amounts of
the PRH expression plasmid pCMV-PRH,
5 mg of the pTK-PRH reporter plasmid,
and 10 mg of the b-galactosidase expres-
sion plasmid pSV-lacZ. The amount of
PRH expression plasmid added is shown
on a logarithimic scale. Relative promoter
activity is the ratio of luciferase activity
in the presence of pCMV-PRH to lucifer-
ase activity in the presence of an equal
amount of the empty pCMV vector. The
luciferase values were normalized with
respect to transfection efficiency using
the cotransfected b-galactosidase plas-
mid. Each transfection was performed a
minimum of three times, and the values
shown represent the means and S.D. C,
BM2 cells were transiently cotransfected
with increasing amounts of pCMV-PRH, 5
mg of the pTK reporter plasmid, and 10 mg
of pSV-lacZ. Details are as in B.
FIG. 2. PRH represses activated
transcription. A, a schematic represen-
tation of the pTK-GAL reporter plasmid.
Five GAL4 binding sites were placed up-
stream of the TK promoter in plasmid
pTK to create pTK-GAL. B, a schematic
representation of the GAL4-activator fu-
sion proteins used in this study. Activa-
tion domains from VP16, Sp1, and HIV
TAT were cloned in frame with the GAL4
DBD (for details see “Materials and Meth-
ods”). C, BM2 cells were transiently co-
transfected with increasing amounts of
pCMV-PRH, 5 mg of the pTK-GAL re-
porter plasmid, 10 mg of pSV-lacZ, and
either GAL4-VP16 (100 ng), GAL4-Sp1
(50 ng), GAL4-TAT (200 ng), or GAL4
DBD (200 ng). Relative promoter activity
is shown on a logarithmic scale. All other
details are as described in Fig. 1B.
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the TATA box and block the binding of TBP (20). To investigate
whether the TATA box is an important element in binding
site-independent transcriptional repression by PRH, we exam-
ined the effect of PRH on transcription from the two promoters
shown in Fig. 3A. The enhancer-less SV40 early promoter con-
sists of a TATA box and six Sp1 binding sites (43) and is present
upstream of the luciferase gene in the pGL-2 Promoter vector
(Promega). The human Surf-1 promoter (HS-1) is a TATA-less
housekeeping promoter, which consists of an Sp1 binding site,
two binding sites for members of the ETS family of transcrip-
tion factors, and a YY1 binding site and is present upstream of
the luciferase gene in the pGL2-Basic vector (37). These two
reporters were transiently transfected into BM2 cells along
with increasing amounts of pCMV-PRH (Fig. 3, B and C, re-
spectively). As in the case of the TATA box containing TK
promoter, 100 ng of pCMV-PRH is sufficient to bring about a
50% repression of SV40 promoter activity. In contrast, the
same amount of pCMV-PRH has no effect on the TATA-less
HS1 promoter and even 50–100-fold higher amounts of pCMV-
PRH bring about only partial repression. Taken together with
the data shown in Fig. 1, these experiments show that PRH is
capable of strongly repressing two different TATA box contain-
ing promoters but is very inefficient at repressing a promoter
that lacks a TATA box. These results suggest that the sensi-
tivity of the TK and SV40 promoters to repression by PRH
might be due to the TATA element.
PRH Binds to the TK TATA Box—An alignment of the con-
sensus PRH binding site with the TK and SV40 TATA boxes
shows that these sequences are very similar (Fig. 4A). The TK
and SV40 TATA boxes deviate from the core consensus PRH
binding site at 1 of 7 and at 2 of 7 positions, respectively. To
determine whether PRH is capable of binding to the TK TATA
box, we expressed a histidine-tagged fragment of PRH compris-
ing the homeodomain and C-terminal region (amino acids 137–
277) in bacterial cells. The histidine-tagged PRH137–277 pro-
tein was purified by chromatography over a nickel column (see
“Materials and Methods”). Fig. 4B shows the results of an
electrophoretic mobility shift assay in which PRH137–277 was
added to labeled DNA carrying the TK TATA box. After 30 min
at 4 °C, protein-DNA complexes were separated from free DNA
FIG. 3. PRH strongly represses TATA box dependent promot-
ers. A, the top line is a schematic representation of the pGL-2 Promoter
vector (Promega). This reporter plasmid contains the SV40 promoter
upstream of the luciferase gene. The bottom line is a schematic repre-
sentation of the HS1 reporter plasmid. This construct contains se-
quences from the HS1 promoter (from 2180 to 120) cloned upstream of
the luciferase gene in pGL-2 basic. B, BM2 cells were transiently
cotransfected with increasing amounts of pCMV-PRH, 5 mg of the
pGL-2 Promoter vector (SV40), and 10 mg of the b-galactosidase expres-
sion plasmid pRSV-lacZ. Details are as in Fig. 1B. C, BM2 cells were
transiently cotransfected with increasing amounts of pCMV-PRH, 5 mg
of the HS1 reporter plasmid, and 10 mg of pRSV-lacZ. Details are as in
Fig. 1B.
FIG. 4. PRH binds to the TK TATA box. A, an alignment of the core
consensus PRH binding site (top line) with the TATA boxes from the TK
promoter (middle line) and SV40 promoter (bottom line). B, a labeled
oligonucleotide carrying the TK TATA box was incubated with histi-
dine-tagged PRH137–277 under the conditions described in the text.
Free and bound DNA was resolved on a 6% polyacrylamide gel and
visualized using a PhosphorImager. The addition of 100 ng PRH results
in the formation of a retarded complex (PRH-DNAC). The complex was
competed away by the addition of 500 ng or 1000 ng of unlabeled TK
TATA box (lanes 2 and 3, respectively) but not by equal amounts of an
unrelated oligonucleotide carrying an HPV 16 E2 binding site (lanes 4
and 5, respectively).
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by electrophoresis on a 6% nondenaturing polyacrylamide gel
and visualized by autoradiography. The addition of PRH re-
sults in the formation of a protein-DNA complex (Fig. 4B, lane
1). To investigate the specificity of this complex, we added
competitor oligonucleotides to the binding reaction. Addition of
an unlabeled oligonucleotide carrying the TK TATA box abol-
ishes the binding of PRH to the labeled DNA (Fig. 4B, lanes 2
and 3). In contrast, addition of an unlabeled oligonucleotide
carrying an unrelated DNA sequence did not compete away the
PRH-TATA box complex (Fig. 4B, lanes 4 and 5). These data
show that PRH is capable of binding to the TK TATA box and
is thus capable of binding to the TK promoter even in the
absence of upstream PRH binding sites.
The Homeodomain Mediates PRH Binding Site-independent
Repression—The experiments described above strongly impli-
cate the homeodomain in the ability of PRH to repress tran-
scription from the TK promoter in the absence of upstream
PRH binding sites. To determine whether the binding of PRH
to the TATA box brings about transcriptional repression, the
homeodomain of PRH was mutated to abrogate its DNA bind-
ing activity. One of the invariant amino acids in all homeodo-
mains is asparagine 51. This amino acid in the En homeodo-
main makes bidentate hydrogen bonds to adenine 13 of the En
binding site, and this contact is crucial for DNA binding (44).
The equivalent residue within the PRH homeodomain (aspar-
agine 194) was mutated to an alanine using site-directed mu-
tagenesis. To confirm that the N194A mutation blocks DNA
binding, we first introduced this mutation into the histidine-
tagged PRH137–277 protein. The resulting histidine-tagged
PRHHDM137–277 protein was expressed in bacteria and puri-
fied exactly as described above (Fig. 5A). CD was used to
determine whether the N194A mutation altered the folding of
the PRHHDM137–277 protein. The CD spectra for PRH137–277
and PRHHDM137–277 are very similar, implying that the mu-
tation has no effect on protein folding or stability (Fig. 5B).
Increasing amounts of PRH137–277 and PRHHDM137–277
were added to labeled DNA carrying the TK TATA box, and
DNA binding activity was assayed as described above. The
FIG. 5. The homeodomain mediates
repression in the absence of up-
stream PRH binding sites. A, histi-
dine-tagged PRH 137–277 (WT) and his-
tidine-tagged PRHHDM 137–277 contain-
ing the N194A mutation (HDM) were pu-
rified over an Ni21-NTA-agarose column
and the eluted proteins analyzed by SDS-
PAGE. M, markers; RM, rainbow mark-
ers. B, circular dichroism was used to de-
termine whether the presence of the
N194A mutation affected the folding or
stability of PRHHDM 137–277. C, a labeled
oligonucleotide carrying the TK TATA
box was incubated with 16, 80, 400, or
2000 ng of histidine-tagged PRHHDM 137–
277 (lanes 2–5) or equal amounts of the
histidine-tagged PRH137–277 (lanes
7–10) under the conditions described in
the text. Free and bound DNA was re-
solved on a 6% polyacrylamide gel and
visualized using a PhosphorImager. D
BM2 cells were transiently cotransfected
with increasing amounts of pGAL-PRH
(empty circles) or pGAL-PRHHDM (filled
circles), along with 5 mg of the pTK re-
porter plasmid and 10 mg of pSV-lacZ.
Other details are as in Fig. 1B. E, the
experiment shown in D was repeated us-
ing the pTK-GAL reporter plasmid. F, in
vitro transcribed and translated TBP
(lane 1) was incubated with Ni21-NTA-
agarose beads carrying histidine-tagged
PRH 137–277 (lane 2), Ni21-NTA-agarose
carrying histidine-tagged PRHHDM 137–
277 (lane 3), or Ni21-NTA-agarose beads
alone (lane 4) under the conditions de-
scribed in the text. After extensive
washes, bound TBP was removed from
the beads using imidazole, run on an
SDS-PAGE gel, and visualized using a
PhosphorImager.
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PRHHDM137–277 protein shows little DNA binding activity
(Fig. 5C, lanes 2–5), whereas at equal protein concentrations,
PRH137–277 binds tightly to the labeled fragment (Fig. 5C,
lanes 7–10).
To determine the effects of the N194A mutation on the abil-
ity of PRH to repress transcription from the TK promoter, this
mutation was introduced into the full-length PRH cDNA in the
context of a GAL4-PRH fusion. The resulting GAL4-PRHHDM
and GAL4-PRH expression plasmids were cotransfected into
BM2 cells along with the TK reporter. The effects of GAL4-
PRHHDM and GAL4-PRH on transcription were compared with
the effect of the GAL4 DBD alone, and transfection efficiency
was measured as before. GAL4-PRH brings about a significant
repression of transcription from the TK promoter when as little
as 50 ng of expression plasmid is cotransfected (Fig. 5D). In
contrast, equivalent amounts of the GAL4-PRHHDM expression
plasmid have little or no effect on the TK promoter (Fig. 5D).
However, with higher amounts of cotransfected GAL4-PRH-
HDM expression plasmid (100 ng), TK promoter activity is par-
tially repressed. These data are consistent with the idea that
PRH represses transcription at the TK promoter by binding to
the TK TATA box. It is possible that the transcriptional repres-
sion seen in the presence of high levels of the GAL4-PRHHDM
expression plasmid results from the low level of TATA box
binding activity shown by the mutated homeodomain (Fig. 5C,
lane 5).
To determine whether binding to the TATA box is the only
mechanism whereby PRH can repress transcription, we next
looked at the ability of the GAL4-PRHHDM protein to repress
transcription when tethered upstream of the TATA box at
GAL4 binding sites. The GAL4-PRH and GAL4-PRHHDM ex-
pression plasmids were cotransfected into BM2 cells along with
the TK-GAL reporter, and promoter activity was assayed as
before. As can be seen from the data shown in Fig. 5E, there is
little if any difference in the ability of these proteins to repress
the TK-GAL promoter. Therefore, PRH must repress transcrip-
tion using at least two mechanisms, one of which is dependent
upon the DNA binding activity of the homeodomain and one of
which is independent of the homeodomain-DNA interaction. In
addition, because both of these GAL4 fusion proteins repress
the TK-GAL promoter equally, this experiment shows that the
wild type protein and the mutated protein are probably ex-
pressed at equivalent levels.
The Eve homeodomain is involved in binding to TBP (45). To
determine whether the PRH homeodomain can interact with
TBP, we performed in vitro binding assays. The PRH137–277
and PRHHDM137–277 proteins described above were incubated
with in vitro transcribed and translated TBP. Labeled TBP
binds strongly to beads coated with either PRH137–277 or
PRHHDM137–277 but binds only very weakly to uncoated beads
(Fig. 5F). Thus, PRH can bind directly to the TATA box and can
also bind TBP. Furthermore, although the N194A mutation
significantly reduces the DNA binding activity of the PRH
homeodomain, this mutation has no effect on the ability of
PRH137–277 to bind TBP. The ability of PRHHDM137–277 to
bind TBP might be another explanation for the transcriptional
repression observed when high amounts of the GAL4-PRHHDM
expression plasmid are cotransfected with the TK promoter
(Fig. 5D).
Mapping the PRH Repression Domains—The N194A muta-
tion abolishes the DNA binding activity of the PRH homeodo-
main and significantly reduces the ability of PRH to repress
transcription from the TK promoter. However, this mutation
does not affect the ability of PRH to repress transcription when
tethered upstream of the TK promoter by the GAL4 DNA-
binding domain. This suggests that when bound upstream of
the promoter, PRH might repress transcription via protein-
protein interactions with TBP and/or via homeodomain-inde-
pendent mechanisms. To delineate the regions of PRH that
function as repression domains, a number of deletions mutants
of PRH were assayed for their ability to repress transcription in
transient transfection experiments. The GAL4-PRH expression
plasmid described above was cotransfected into BM2 cells
along with either the TK or TK-GAL reporter plasmids. The
addition of 1 mg of the GAL4-PRH expression plasmid brings
about 100% repression of the TK-GAL promoter, and 95% re-
pression of the TK promoter (Fig. 6, first line). Because 1 mg of
GAL4-PRH is sufficient to give almost complete repression of
both the TK and TK-GAL promoters, this amount of expressor
plasmid was chosen for all subsequent transfections. A series of
deletion mutants of PRH were placed in frame with the GAL4
DBD in pMLV-GAL147plink. As can be seen from the data
(Fig. 6, second line), the N-terminal 141 amino acids of PRH
(which excludes the PRH homeodomain) are sufficient to bring
about full repression of the TK-GAL promoter. However, this
fusion protein does not repress the TK promoter. Thus, PRH
contains a proline-rich N-terminal repression domain that
functions when tethered to a promoter either via the PRH
homeodomain or via the GAL4 DBD. The C-terminal 134 amino
acids of PRH (aa 143–277), which includes the PRH homeodo-
main, brings about full repression of both TK reporters (Fig. 6,
fourth line), and a further deletion of amino acids 210–277
shows that the PRH homeodomain alone is sufficient to repress
transcription from the TK promoter (Fig. 6, fifth line). In con-
trast, the C-terminal amino acids from 202–277 only weakly
repress transcription (Fig. 6, sixth line). These data confirm
that the PRH homeodomain is responsible for the repression of
the TK promoter seen in the absence of upstream PRH binding
sites. The C-terminal acidic region of PRH might contribute to
repression by the homeodomain (Fig. 6, compare fourth and
fifth lines); however, the increased repression seen in the pres-
ence of this region might be a consequence of increased protein
expression and/or stability.
Deletion Analysis of the Proline-rich Repression Domain—
The proline-rich N-terminal 141 amino acids of PRH function
as an independent transferable repression domain. To investi-
FIG. 6. PRH contains at least two independent transcriptional
repression domains. A series of GAL4-PRH fusion proteins were
assayed for their ability to repress transcription from the pTK reporter
(solid bars) and the pTK-GAL reporter (empty bars). BM2 cells were
transiently cotransfected with 1 mg of each GAL4-PRH expression plas-
mid, 5 mg of the each reporter plasmid, and 10 mg of pSV-lacZ. The
difference between TK promoter activity in the presence of the GAL4
DBD alone and TK promoter activity in the presence of full-length PRH
(PRH1–277) fused to the GAL4 DBD was taken to represent 100%
repression. All other details are as described in Fig. 1B. NA, not
assayed.
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gate this repression domain, a series of deletion fragments from
the PRH N terminus were fused in frame with the GAL4 DBD.
The proline-rich domain was deleted in ;20-amino acid inter-
vals from the N terminus to amino acid 107. Because we were
unable to detect protein expression levels for any of these
constructs in BM2 cells (data not shown), we transiently trans-
fected these constructs into QT6 cells, a quail fibroblast cell
line. We first established that the PRH N terminus can repress
transcription in quail fibroblasts and is detectable by Western
experiments (Fig. 7, A, first line, and C, first track). This sug-
gests that the proline-rich repression domain is functional in
these cells and that there are no essential species-specific or
cell-type requirements for the activity of this domain. Interest-
ingly none of the deletions that remove N-terminal amino acids
greatly affect repression (Fig. 7A). Although the GAL4-PRH
81–141 and GAL4-PRH 107–141 constructs appear to repress
somewhat less well than the GAL4-PRH 1–141 construct, the
former are expressed at virtually undetectable levels (Fig. 7C,
fourth and fifth tracks, compared with first track). However,
both GAL4-PRH 81–141 and GAL4-PRH 107–141 still bring
about at least 50% repression of the TK-GAL promoter (Fig. 7A,
fourth and fifth lines). Thus, the 34 amino acids from 107 to 141
can function as a repression domain.
Fig. 7B shows the effect of deletions into the C terminus of
the proline-rich repression domain. Deletion of the C-terminal
16 amino acids to create GAL4-PRH 1–125 has a minor effect
on repression (Fig. 7B, second line). A further deletion of 20
amino acids to produce GAL4-PRH 1–105 completely abolishes
repression (Fig. 7B, third line). However, although the GAL4-
PRH 1–105 construct completely fails to repress transcription,
it is expressed in QT6 fibroblasts at a much lower level than
GAL4-PRH 1–125 (Fig. 7C). Although these data suggest that
amino acids 105–141 are essential for repression, two further
deletion constructs indicate that this is not the case. PRH
derivatives GAL4-PRH 28–141 and GAL4-PRH 28–105 both
strongly repress transcription and are both strongly expressed
in these cells (Fig. 7B, fourth and fifth lines). Thus the 77 amino
acids from 28 to 105 can also function as a repression domain.
One possible explanation for the lack of repression by GAL4-
PRH 1–105 is that although this construct is expressed, (albeit
at low level), it may be misfolded and either no longer interacts
or interacts aberrantly with the transcription apparatus.
Taken together with the experiments described in Fig. 7A,
these data suggest that the N-terminal repression domain is
composed of at least two elements that can independently bring
about repression. The first element lies within the region 28–
105 of PRH, and the second element lies within the region
107–141. Thus, the PRH proline-rich repression domain is not
composed of a single discrete region that is essential for tran-
scriptional repression but may instead be composed of multiple
regions that are independently capable of transcriptional
repression.
DISCUSSION
Using a series of truncated proteins, we have shown that
PRH contains two independently acting transcription repres-
sion domains. One repression domain consists of the PRH
homeodomain, whereas the other consists of the proline-rich
N-terminal region of the protein. The homeodomain proteins
Eve and Msx-1 can bind directly to TBP, and these interactions
are probably important for transcriptional repression (25, 26,
45). Although PRH is similar to Eve in that it can also bind
directly to both TBP and DNA, the mechanism of repression
appears to be different. Mutations in the Eve homeodomain
that block binding to DNA have no effect on the binding of this
protein to TBP and do not prevent Eve from repressing tran-
scription (45). In direct contrast, a mutation in the PRH homeo-
domain that blocks binding to DNA has no effect on the binding
of this protein to TBP but significantly reduces transcriptional
repression. These data suggest that PRH might repress tran-
scription by binding to the TATA box and sterically hinder the
FIG. 7. Fine mapping of the PRH N-terminal repression do-
main. A, defining the N-terminal boundary of the proline-rich repres-
sion domain. The series of GAL4-PRH fusion proteins shown in the
figure were assayed for their ability to repress transcription from the
pTK-GAL reporter. QT6 cells were transiently cotransfected with 1 mg
of each GAL4-PRH expression plasmid, 5 mg of pTK-GAL, and 5 mg of
pSV-lacZ. The percentage repression was determined as described in
Fig. 6. B, defining the C-terminal boundary of the proline-rich repres-
sion domain. The series of GAL4-PRH fusion proteins shown in the
figure were assayed for their ability to repress transcription from the
pTK-GAL reporter exactly as described in A. C, a Western blot of the
GAL4-PRH N-terminal fusion proteins after transient transfection into
QT6 cells. Proteins were probed with a monoclonal antibody against the
GAL4 DBD, and specific antibody binding was detected by ECL. The
bracket marks the positions of the fusion proteins. The other bands are
endogenous proteins that cross-react with the antibody.
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binding of TBP. This mechanism of repression has been ob-
served previously in vitro for the En protein (20). However, this
is the first strong evidence to suggest that a homeodomain
protein can regulate transcription in intact cells using this
passive repression mechanism. Several observations support
this conclusion. First, repression by the full-length PRH pro-
tein does not require the presence of PRH binding sites up-
stream of the target promoter. Second, PRH can bind to an
oligonucleotide carrying the TK TATA box in vitro. Third, PRH
is capable of repressing transcription from TATA box contain-
ing promoters but is very inefficient at repressing transcription
from a TATA-less promoter. Fourth, the PRH homeodomain
alone is able to repress transcription in vivo. Interestingly,
although En and PRH seem to use a similar mechanism for the
repression of transcription, PRH unlike En, can interact di-
rectly with TBP. To determine whether TBP and PRH can form
a tripartite complex with DNA, we carried out electrophoretic
mobility shift assay with both proteins. However, TBP was
unable to bind to the TK TATA box under conditions that
allowed the strong binding of PRH. Thus, the functional signif-
icance of the TBP-PRH interaction could not be assessed using
this method. The possibility remains, therefore, that in addi-
tion to the passive repression mechanism observed at this
promoter, under some circumstances the PRH homeodomain
might also repress by direct repression of the basal transcrip-
tion complex by interaction with TBP.
Proline-rich transcription repression domains have been
identified in a number of homeodomain proteins including Eve,
Msx-1, and Evx-1 (35, 46, 47). The Eve proline-rich repression
domain is involved in mediating protein-protein interactions
that result in the cooperative binding of Eve to DNA (21).
However, it is not yet clear how proline-rich domains bring
about repression. The proline-rich PRH N-terminal domain
represses transcription when tethered upstream of a promoter
both in the hematopoietic BM2 cell line and also in QT6 fibro-
blasts. Deletions within the PRH N terminus showed that
there are at least two regions within the PRH N terminus that
are capable of significantly repressing transcription. Region
28–105 of PRH is both strongly expressed in QT6 fibroblasts
and shows strong repression activity. Region 107–141 of PRH,
although not detectable in Western experiments, also displays
significant repression activity. Thus, we infer that there are at
least two nonoverlapping regions within this domain that can
function independently. Han and Manley (48) have shown that
a proline-leucine-rich peptide only 27 amino acids in length is
capable of acting as a potent repressor in transient transfection
assays; they suggest that a key feature of a repression domain
is that it is relatively unstructured and hydrophobic. In keep-
ing with this view, region 28–105 of PRH contains a large
proportion of alanine (14%), proline (23%), and leucine (6%)
residues. However, the 34-amino acid region (107–141) con-
tains only 11% proline residues and 11% leucine residues.
Studies on the Wilm’s tumor (WT) protein repression domain
have shown that proline residues outside the WT minimal
repression domain are important for repression. These proline
residues may aid the accessibility of key amino acids from the
WT minimal repression domain with interacting proteins (49).
Similarly, it is possible that the proline and leucine residues
from region 107–141 in PRH may allow other amino acids
within this region to be more accessible to any interacting
proteins.
There are two sequences within the PRH N terminus that
might mediate interactions with other transcription factors.
The first sequence LLWSPF (amino acids 131–136 in avian
PRH and 124–129 in human PRH) is located 7 amino acids
upstream of the PRH homeodomain and is within the region
107–141. Hexapeptide sequences that loosely match this motif
are located upstream of the homeodomain in several members
of the HOX family of transcription factors, and HOX proteins
use these sequences to contact members of the PBC family of
homeodomain proteins (50). The PBC proteins modulate tran-
scription of the HOX proteins by altering either their binding
specificity (4) or their transcriptional regulatory properties (5,
6). Similar tryptophan containing sequences (WRPY and
WRPW) are also found in proteins that recruit the Drosophila
corepressor protein Groucho (51, 52). The second sequence
TPFYIEDILGR (amino acids 33–43 in avian PRH and 30–40
in human PRH) is present in region 28–105. This sequence
strongly resembles the eh1 motif found in En that mediates the
interaction of En with Groucho (34). Deletions in PRH that
remove either this putative eh1 motif or the LLWSPF sequence
do not block transcriptional repression. One possibility is that
the PRH N terminus interacts with multiple proteins or that
any interacting proteins might make several contacts with the
PRH N terminus and that the removal of any one contact might
only partially block the interaction. Certainly in the case of the
interaction of TLE1, the human equivalent of Groucho, with
the AML1 protein, several regions of AML1 are important for
the interaction (40).
In summary, the PRH homeodomain can passively repress
transcription by binding to TATA box sequences. However, the
proline-rich repression domain of PRH also represses tran-
scription and may do so by interacting with basal transcription
factors or by altering chromatin structure in conjunction with
corepressors. We have shown previously that the proline-rich
domain of PRH plays a role in the control of cell growth and
differentiation in the hematopoietic compartment (16). Future
experiments may allow us to determine which of these repres-
sion mechanisms are important for the function of PRH in vivo.
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